Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC lowered its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 58.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 30,348 shares of the biotechnology company's stock after selling 41,900 shares during the quarter. Conestoga Capital Advisors LLC's holdings in Axon Enterprise were worth $15,962,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fourth Dimension Wealth LLC acquired a new stake in shares of Axon Enterprise during the fourth quarter worth $30,000. Elequin Capital LP acquired a new position in shares of Axon Enterprise during the 4th quarter valued at about $46,000. CoreFirst Bank & Trust purchased a new position in shares of Axon Enterprise during the 4th quarter worth about $59,000. Global Financial Private Client LLC raised its stake in Axon Enterprise by 11,100.0% during the first quarter. Global Financial Private Client LLC now owns 112 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 111 shares during the period. Finally, Prestige Wealth Management Group LLC raised its position in shares of Axon Enterprise by 59.8% in the 4th quarter. Prestige Wealth Management Group LLC now owns 131 shares of the biotechnology company's stock worth $78,000 after buying an additional 49 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on AXON shares. Needham & Company LLC boosted their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Barclays boosted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Bank of America lifted their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Finally, Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $780.61 on Tuesday. The firm has a 50-day moving average of $675.00 and a two-hundred day moving average of $622.37. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a market cap of $60.77 billion, a P/E ratio of 201.71, a PEG ratio of 5.17 and a beta of 1.29. Axon Enterprise, Inc. has a 1-year low of $279.02 and a 1-year high of $806.64.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. During the same quarter in the previous year, the firm posted $1.15 earnings per share. The company's revenue was up 31.3% compared to the same quarter last year. On average, research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In related news, Director Julie A. Cullivan sold 657 shares of Axon Enterprise stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $700.00, for a total value of $459,900.00. Following the completion of the transaction, the director now directly owns 1,735 shares in the company, valued at approximately $1,214,500. This trade represents a 27.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares in the company, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,737 shares of company stock valued at $29,797,795 over the last ninety days. Corporate insiders own 4.40% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.